Roche's CT-388 Obesity Data Tests New Growth Pillar Potential [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
Roche Holding (SWX:ROG) reported significant weight loss results from Phase II trials of its dual GLP-1/GIP obesity candidate CT-388. The company plans protocol adjustments for upcoming Phase III studies to manage side effects linked to earlier dosing approaches. The data also included improved blood glucose control, pointing to potential relevance in broader cardiometabolic care. For you as an investor, CT-388 places Roche in the fast growing obesity and cardiometabolic drug segment, an area attracting heavy R&D and capital across the sector. SWX:ROG has long been associated with oncology and specialty medicines, so this obesity program adds a different pillar to its late stage pipeline. The next step will be how Roche designs and executes the Phase III program, particularly its approach to dosing and side effect management. Market attention is likely to focus on whether CT-388 can secure a position in an increasingly crowded weight management field and how that could influe
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging [Yahoo! Finance]Yahoo! Finance
- SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech [Yahoo! Finance]Yahoo! Finance
- Natera Submits Signatera™ CDx PMA to FDA [Yahoo! Finance]Yahoo! Finance
- Diagnostic Enzymes Research Report 2026 - Global $8.72 Bn Market Trends, Opportunities, and Forecasts to 2031 [Yahoo! Finance]Yahoo! Finance
- Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha